Is compounded semaglutide still legal in 2026?
Written by
glpzoom Editorial Team
Medically reviewed
Against primary clinical sources- Apr 0 2026
- FDA proposed permanent ban
- 0+
- FDA warning letters in 2026
- Feb 0 2026
- Hims exited compounded GLP-1
- Jun 0 2026
- FDA comment period closes
For two years, compounded semaglutide was the affordable on-ramp to GLP-1 weight loss. A drug shortage gave compounding pharmacies legal cover to produce it at scale, and telehealth platforms built entire businesses on the price gap between a $200/month compound and a $1,350/month branded pen. That era is ending.
The shortage was declared resolved in late 2024. On April 30, 2026, the FDA went further: it proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, finding no clinical need for outsourcing facilities to compound these drugs. It issued 30 warning letters and opened a public comment period through June 29, 2026.
If the rule is finalized, large-scale compounded semaglutide and tirzepatide effectively end. The bellwether already happened: Hims & Hers exited the compounded GLP-1 market in February 2026 and now sells brand-name Wegovy only.
Frequently asked questions
- Is compounded semaglutide legal right now (May 2026)?
- It exists in a narrowing legal grey zone. The 2022-2024 shortage that made mass compounding legal ended in late 2024. As of April 30, 2026, the FDA proposed permanently removing semaglutide from the 503B bulk-compounding list and issued 30 warning letters. Compounding for genuine individual clinical needs (documented allergy to an inactive ingredient, a dose not commercially made) may still be permitted under 503A, but routine 'cheaper alternative' compounding is being shut down.
- What happens to my prescription if the FDA finalizes the rule?
- Your compounding pharmacy would lose the legal basis to produce semaglutide or tirzepatide at scale. Most patients will need to transition to branded Wegovy, Ozempic, Zepbound, or Mounjaro, or to a manufacturer direct-pay channel (NovoCare, LillyDirect). Talk to your prescriber before the comment period closes June 29, 2026.
- Did Hims stop selling compounded semaglutide?
- Yes. On February 7, 2026, Hims & Hers exited the compounded GLP-1 market amid regulatory pressure and a Novo Nordisk lawsuit. Hims now sells brand-name Wegovy only. Several other large platforms have followed.
- Is compounded semaglutide safe?
- Compounded drugs do not undergo FDA review for safety, efficacy, or manufacturing quality. Quality varies by pharmacy. The FDA has documented dosing errors and contamination concerns in some compounded GLP-1 products. If you use a compounded version, confirm the dispensing pharmacy is 503A or 503B registered and ask which facility produces the compound.
- What are my cheaper options if compounded goes away?
- Manufacturer direct-pay channels narrowed the gap: NovoCare self-pay and LillyDirect offer branded GLP-1s at $399-549/month for eligible cash-pay patients. Orforglipron, Lilly's new oral pill, launches at $149/month via LillyDirect. Insurance with prior authorization remains the cheapest path when available.
Your options as compounding ends
Primary sources: Pharmacy Times, Medscape, National Law Review.